Thomasville National Bank Has $16.62 Million Holdings in GSK plc (NYSE:GSK)

Thomasville National Bank lifted its position in shares of GSK plc (NYSE:GSK) by 3.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 491,441 shares of the pharmaceutical company’s stock after purchasing an additional 16,057 shares during the quarter. GSK accounts for 1.2% of Thomasville National Bank’s investment portfolio, making the stock its 29th largest holding. Thomasville National Bank’s holdings in GSK were worth $16,621,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. FMR LLC raised its position in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC raised its position in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Primecap Management Co. CA raised its position in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after purchasing an additional 342,365 shares during the period. Provident Trust Co. raised its position in shares of GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after purchasing an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC raised its position in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

Shares of NYSE:GSK traded down $0.44 on Monday, hitting $32.65. The company’s stock had a trading volume of 2,221,377 shares, compared to its average volume of 2,834,607. The company has a 50-day simple moving average of $34.38 and a 200 day simple moving average of $38.17. GSK plc has a 1 year low of $32.55 and a 1 year high of $45.92. The company has a market capitalization of $67.67 billion, a PE ratio of 21.20, a PEG ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were issued a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.81%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. GSK’s dividend payout ratio (DPR) is currently 95.45%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.